Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) has earned a consensus recommendation of “Buy” from the eight brokerages that are covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have covered the stock in the last year is $145.71.
Several brokerages have weighed in on PCVX. The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, November 6th.
Get Our Latest Analysis on PCVX
Insider Activity at Vaxcyte
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in PCVX. Riverview Trust Co acquired a new position in shares of Vaxcyte during the third quarter worth $27,000. Blue Trust Inc. lifted its holdings in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after buying an additional 93 shares in the last quarter. Meeder Asset Management Inc. lifted its holdings in Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after buying an additional 635 shares in the last quarter. Nomura Asset Management Co. Ltd. purchased a new position in Vaxcyte in the 3rd quarter valued at about $92,000. Finally, Signaturefd LLC grew its stake in shares of Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock valued at $120,000 after acquiring an additional 358 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.
Vaxcyte Stock Up 2.0 %
PCVX opened at $86.51 on Friday. The firm has a market cap of $10.78 billion, a P/E ratio of -18.81 and a beta of 0.98. The business’s fifty day simple moving average is $87.46 and its 200 day simple moving average is $94.42. Vaxcyte has a 52 week low of $58.10 and a 52 week high of $121.06.
Vaxcyte (NASDAQ:PCVX – Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the firm earned ($0.91) EPS. As a group, equities analysts expect that Vaxcyte will post -4.21 EPS for the current fiscal year.
About Vaxcyte
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Featured Articles
- Five stocks we like better than Vaxcyte
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- How to Short a Stock in 5 Easy Steps
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.